Mzikazi Fuzile’s Post

🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/BlUTnk 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/m4QyZ1 #oncology #oncologyresearch #ProductCitation

🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/R6k34m 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/ZU94BL #oncology #oncologyresearch #ProductCitation

𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐓𝐨 https://lnkd.in/euN7Z8i8 𝐠𝐞𝐭 𝐰𝐞𝐥𝐥-𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 The Mexico Antibody Drug Conjugates (ADC) Market is paving the way for groundbreaking advancements in oncology. Combining the precision of antibodies with the potency of cytotoxic drugs, ADCs are redefining cancer treatment by targeting cancer cells while sparing healthy tissue. With increasing investments in biotech R&D and growing adoption of personalized medicine, Mexico is emerging as a key player in the ADC landscape. 🚀 The future of oncology is here—focused, effective, and life-changing. To Get more:https://lnkd.in/dCyCfKzM #AntibodyDrugConjugates #OncologyInnovation #BiotechMexico #TargetedTherapies #PharmaTrends"

What is a checkpoint inhibitor? In our new CEO spotlight series, Vlad Vitoc, MD, MBA, dives into this drug that helps the immune system attack cancer cells. Find out by watching the video clip below and stay tuned for more as Vlad brings you firsthand insights from the #biotech world. #Oncology #OncNews #Immunotherapy

What is a checkpoint inhibitor? Watch as a dive into this immunotherapy agent, a type of drug that helps the immune system attack cancer cells. I'm Dr. Vlad Vitoc, Founder and CEO of MAIA Biotechnology, Inc. bringing you firsthand insights from the #biotech world. #Oncology #OncNews #Immunotherapy

Another exciting collaboration with C&EN BrandLab! This article explores the transformative role of small molecule oncology drugs in cancer treatment, highlighting how innovative approaches are overcoming therapeutic challenges and advancing patient care. 🧬✨ The piece delves into the unique benefits of small molecules, recent breakthroughs in drug development, and how industry leaders like Lonza are helping to accelerate these innovations. A special thank you to Lonza's expert, Charlie Johnson, for sharing invaluable expertise and insights that brought this piece to life. Don’t miss it—check it out here: https://lnkd.in/emeMq_iC #LonzaSM #Oncology #Innovation #SmallMolecules

🚨 The Future of Oncology: Next-Gen ADCs are Here! 🧬 Antibody-drug conjugates (ADCs) are entering their golden age, revolutionising cancer treatment by combining targeted therapy with potent cytotoxic drugs. This $12B market is projected to hit $44B by 2029! 🚀 Highlights: 🔬 Advanced payload & linker tech is widening therapeutic windows. 💊 ZAI Lab, Sutro Biopharma, Inc., and ADC Therapeutics are leading innovation. 💡 Beyond cancer: ADCs could tackle autoimmune diseases in the future! #Oncology #ADCTherapeutics #Biotech #CancerCare #Innovation

💡 Join Crown Bioscience for an upcoming webinar to explore the significant hurdle of cancer drug resistance, one of the greatest challenges in developing effective cancer therapeutics. 💊 Dr. Rajendra Kumari will discuss the evolving landscape of drug resistance, focusing on preclinical tools and strategies that can accelerate therapeutic discovery and provide actionable insights. Attendees will gain insights into specific models developed to study resistance to targeted therapies and immunotherapeutics, along with their features and practical applications for predicting clinical outcomes. ➡️ Learn more + register here: https://buff.ly/4eagwr7 #DrugDevelopment #DrugDiscovery #DrugResistance #Oncology #TherapeuticAreas #OncologyDrugDevelopment #CancerTherapy #PreClinical #CellAndGeneTherapies

Delve into the molecular intricacies of cancer with DRUG-seq, an affordable and efficient RNA-seq application that is changing the landscape of oncology drug discovery. This state-of-the-art technology drives innovation in investigating mechanisms of drug action, profiling drug responses, discovering biomarkers, and untangling tumor heterogeneity. Contact us to find out how you can use Champions' new DRUG-seq platform to generate fast insights in drug discovery: https://hubs.li/Q02HsjHk0 #DRUGseq #OncologyResearch #CancerResearch #RNAseq #MechanismOfAction #DrugResponse #DrugResistance #BiomarkerDiscovery #TumorHeterogeneity #Oncology #Cancer #PrecisionMedicine #DrugDiscovery #endpointspotlight

Learn about the history and future of small molecule oncology drugs - big thanks to our friends at Lonza for the feature!